IP Library Granted Patent US 8,415,474
Granted Patent B2
US 8,415,474 · App. 12/889,502 · Granted Apr 9, 2013

One-pot preparation of hexahydroisoquinolines from dihydroisoquinolines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,415,474
App. No.
12/889,502
Granted
Apr 9, 2013
Kind
B2
Abstract

The present invention provides an efficient process for the preparation of hexahydroisoquinolines from dihydroisoquinolines. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines.

Claims (51)

1. A one-pot process for the preparation of a compound having Formula (IV) from a mixture of compounds having Formulas (II) and (II′), the process comprising:

(a) contacting the compounds having Formulas (II) and (II′) with an asymmetric catalyst and a hydrogen donor comprising a formate ion to form a mixture of compounds having Formulas (III) and (III′); and

(b) contacting the compounds having Formulas (III) and (III′) with an alkali metal and an electron source to form the compound having Formula (IV) according to the following reaction scheme:

wherein:

R 1 , R 5 , and R 7 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and —OR 111 ;

R 2 and R 6 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, and —OR 211 ;

R 3 is chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and —OR 211 ;

R 4 is chosen from —C(O)R 212 , —C(O)C(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ;

R 12 and R 13 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, and —OR 111 ;

R 111 is chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 211 is chosen from hydrogen, hydrocarbyl, —C(O)R 212 , —C(O)C(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ; and

R 212 is chosen from hydrocarbyl and substituted hydrocarbyl,

and further wherein the compounds haying Formulas (III) and (III′) are not crystallized prior to step (b).

2. The process of claim 1 , wherein a compound chosen from Formulas (IV′), (IV″), and a combination thereof is also formed during step (b):

wherein:

R 1 , R 5 , and R 7 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and —OR 111 ;

R 2 and R 6 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, and —OR 211 ;

R 3 is chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and —OR 211 ;

R 12 and R 13 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, and —OR 111 ;

R 111 is chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 211 is chosen from hydrogen, hydrocarbyl, —C(O)R 212 , —C(O)C(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ; and

R 212 is chosen from hydrocarbyl and substituted hydrocarbyl.

3. The process of claim 1 , wherein:

R 3 is —OR 211 ; R 211 is chosen from hydrogen, alkyl, —C(O)R 212 , —C(O)C(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ; and

R 212 is chosen from alkyl and aryl.

4. The process of claim 1 , wherein:

R 5 is —OR 211 ;

R 211 is chosen from hydrogen, alkyl, —C(O)R 212 , —C(O)C(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ; and

R 212 is chosen from alkyl and aryl.

5. The process of claim 1 , wherein R 1 , R 2 , R 5 , R 7 , R 12 , and R 13 are hydrogen; R 3 and R 6 are methoxy; R 4 is —C(O)R 212 ; and R 212 is chosen from methyl, t-butyl, and phenyl.

6. The process of claim 1 , wherein:

R 3 and R 5 are —OR 211 ;

R 211 is chosen from hydrogen, alkyl, —C(O)R 212 , —C(O)C(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ; and

R 212 is chosen from alkyl and aryl.

7. The process of claim 1 , wherein the asymmetric catalyst comprises a metal or a metal source and a chiral ligand.

8. The process of claim 7 , wherein the metal or metal source is chosen from ruthenium, a ruthenium complex, osmium, an osmium complex, rhodium, a rhodium complex, iridium, an iridium complex, palladium, a palladium complex, platinum, a platinum complex, and combinations thereof.

9. The process of claim 7 , wherein the chiral ligand is a compound chosen from Formula 670, Formula 680, Formula 690, and Formula 700:

wherein:

R 671 , R 672 , R 673 , R 681 , R 691 , R 692 , R 701 , and R 702 are independently alkyl or aryl; and further wherein

R 691 and R 692 of Formula (690) and R 701 and R 702 of Formula (700), and the carbon atoms to which they are attached, may optionally form a cyclic or bicyclic compound.

10. The process of claim 7 , wherein the metal source is dichloro(p-cymene)ruthenium(II) dimer and the chiral ligand is (1S,2S)-(+)-N-4-tolylsulfonyl-1,2-diphenylethylene-1,2-diamine.

11. The process of claim 1 , wherein the weight ratio of the asymmetric catalyst to the compounds having Formulas (II) and (II′) is about 0.001:1 to about 0.1:1.

12. The process of claim 1 , wherein the hydrogen donor is chosen from formic acid, a salt of formic acid, and a mixture of formic acid and an organic base.

13. The process of claim 1 , wherein the hydrogen donor comprises formic acid and triethylamine.

14. The process of claim 1 , wherein the molar ratio of the compounds having Formulas (II) and (II′) to the hydrogen donor is about 1:1 to about 1:20.

15. The process of claim 1 , wherein the alkali metal is chosen from lithium, sodium, and potassium; and the electron source is chosen from liquid ammonia, methylamine, ethylamine, ethylenediamine, and combinations thereof.

16. The process of claim 1 , wherein the alkali metal is lithium and the electron source is liquid ammonia.

17. The process of claim 1 , wherein the molar ratio of the compounds having Formulas (III) and (III′) to the alkali metal is from about 1:2: to about 1:20, and the weight to volume ratio of the compounds having Formulas (III) and (III′) to the electron source is from about 1:2 to about 1:50 (g/mL).

18. The process of claim 1 , wherein step (a) is conducted at a temperature from about 20° C. to about 100° C., and step (b) is conducted at a temperature from about −80° C. to about 10° C.

19. The process of claim 1 , wherein the compound having Formula (IV) has a yield of at least about 60%.

20. The process of claim 1 , wherein the asymmetric catalyst comprises dichloro(p-cymene)ruthenium(II) dimer and either (1S,2S)-(+)-N-4-tolylsulfonyl-1,2-diphenylethylene-1,2-diamine or (1R,2SR)-(+)-N-4-tolylsulfonyl-1,2-diphenylethylene-1,2-diamine; the weight ratio of the asymmetric catalyst to the compounds having Formulas (II) and (II′) is about 0.01:1; the hydrogen donor comprises formic acid and triethylamine; the molar ratio of the compounds having Formulas (II) and (II′) to formic acid to triethylamine is from about 1:4:2 to about 1:6:3; the alkali metal is lithium and the electron source is liquid ammonia; the molar ratio of the compounds having Formulas (III) and (III′) to lithium is from about 1:3 to about 1:10; the weight to volume ratio of the compounds having Formulas (III) and (III′) to liquid ammonia is from about 1:3 to about 1:10 (g/mL); step (a) is conducted at a temperature from about 22° C. to about 25° C.; step (b) is conducted at a temperature from about −70° C. to about −60° C.; and the compound having Formula (IV) has a yield of at least about 60%.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →